{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:33:27Z","timestamp":1768466007755,"version":"3.49.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: We have previously demonstrated an early and potent antiinflammatory effect of troglitazone and rosiglitazone.<\/jats:p>\n               <jats:p>Hypothesis: Because inflammatory mediators interfere with insulin signal transduction, we have now hypothesized that rosiglitazone exerts an initial antiinflammatory effect independently of its metabolic actions including the suppression of the plasma concentration of free fatty acids (FFAs), insulin, and glucose after which insulin sensitization occurs.<\/jats:p>\n               <jats:p>Patient and Methods: Fourteen patients with type 2 diabetes were included in the study. Eight patients were given 2 mg daily of rosiglitazone for 6 wk, whereas the other six patients were given a placebo for the same period.<\/jats:p>\n               <jats:p>Results: After a 2-mg dose of rosiglitazone, plasma FFAs, insulin, and glucose concentrations and homeostasis model assessment of insulin resistance did not change. Plasma C-reactive protein, serum amyloid A, and matrix metalloproteinase concentrations fell significantly at wk 1 and continued to be significantly lower than the baseline levels by 25, 29, and 24%, respectively, at wk 6. Leukocyte count was significantly lower at wk 6 after rosiglitazone, whereas there was no change in the control group. Plasma adiponectin concentrations increased significantly at wk 2 and continued to increase during the treatment period with rosiglitazone. Resistin concentrations fell significantly by 10% at wk 6 only. There were no changes in any of these indices in the placebo group.<\/jats:p>\n               <jats:p>Conclusions: A low dose of rosiglitazone exerts an early and potent antiinflammatory effect with an increase in adiponectin and a fall in resistin concentrations without causing any metabolic changes (fall in plasma glucose, FFAs, and insulin concentrations) over a 6-wk period. The increase in adiponectin and the decrease in resistin after rosiglitazone are thus related primarily to its antiinflammatory effects rather than its metabolic actions. These observations have implications in relation to the mode of action of this drug as an insulin-sensitizing agent and also its use as a potential antiinflammatory and antiatherogenic drug in the future.<\/jats:p>","DOI":"10.1210\/jc.2005-2609","type":"journal-article","created":{"date-parts":[[2006,6,28]],"date-time":"2006-06-28T01:38:01Z","timestamp":1151458681000},"page":"3553-3558","source":"Crossref","is-referenced-by-count":65,"title":["Low-Dose Rosiglitazone Exerts an Antiinflammatory Effect with an Increase in Adiponectin Independently of Free Fatty Acid Fall and Insulin Sensitization in Obese Type 2 Diabetics"],"prefix":"10.1210","volume":"91","author":[{"given":"Husam","family":"Ghanim","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Dhindsa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Aljada","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhakar","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paresh","family":"Dandona","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071613534009000_R1","first-page":"3257","article-title":"Insulin inhibits intranuclear nuclear factor \u03baB and stimulates I\u03baB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?","volume":"86","author":"Dandona","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613534009000_R2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1210\/jcem.87.3.8462","article-title":"Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations","volume":"87","author":"Aljada","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613534009000_R3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/01.HYP.36.3.430","article-title":"Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects","volume":"36","author":"Garg","year":"2000","journal-title":"Hypertension"},{"key":"2020071613534009000_R4","first-page":"1306","article-title":"Suppression of nuclear factor-\u03baB and stimulation of inhibitor \u03baB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese","volume":"86","author":"Ghanim","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613534009000_R5","first-page":"3250","article-title":"Nuclear factor-\u03baB suppressive and inhibitor-\u03baB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?","volume":"86","author":"Aljada","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613534009000_R6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.CIR.0000025403.20953.23","article-title":"Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus","volume":"106","author":"Haffner","year":"2002","journal-title":"Circulation"},{"key":"2020071613534009000_R7","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1210\/jc.2003-032103","article-title":"Evidence for a potent antiinflammatory effect of rosiglitazone","volume":"89","author":"Mohanty","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613534009000_R8","doi-asserted-by":"crossref","first-page":"F600","DOI":"10.1152\/ajprenal.00289.2005","article-title":"Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy","volume":"290","author":"Agarwal","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020071613534009000_R9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.clinthera.2005.05.005","article-title":"Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study","volume":"27","author":"Mattoo","year":"2005","journal-title":"Clin Ther"},{"key":"2020071613534009000_R10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-\u03b3 is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"2020071613534009000_R11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/83336","article-title":"PPAR-\u03b3 dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation","volume":"7","author":"Chawla","year":"2001","journal-title":"Nat Med"},{"key":"2020071613534009000_R12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1172\/JCI7145","article-title":"A novel therapy for colitis utilizing PPAR-\u03b3 ligands to inhibit the epithelial inflammatory response","volume":"104","author":"Su","year":"1999","journal-title":"J Clin Invest"},{"key":"2020071613534009000_R13","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.2337\/diabetes.51.10.2968","article-title":"The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects","volume":"51","author":"Yu","year":"2002","journal-title":"Diabetes"},{"key":"2020071613534009000_R14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diacare.25.2.376","article-title":"Synthetic peroxisome proliferator-activated receptor-\u03b3 agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients","volume":"25","author":"Yang","year":"2002","journal-title":"Diabetes Care"},{"key":"2020071613534009000_R15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1210\/endo.143.3.8662","article-title":"Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR\u03b3 agonists: a potential mechanism of insulin sensitization","volume":"143","author":"Combs","year":"2002","journal-title":"Endocrinology"},{"key":"2020071613534009000_R16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan","year":"2001","journal-title":"Nature"},{"key":"2020071613534009000_R17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0006-291X(02)02841-3","article-title":"Resistin is expressed in human macrophages and directly regulated by PPAR\u03b3 activators","volume":"300","author":"Patel","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071613534009000_R18","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.CIR.0000155620.10387.43","article-title":"Resistin is an inflammatory marker of atherosclerosis in humans","volume":"111","author":"Reilly","year":"2005","journal-title":"Circulation"},{"key":"2020071613534009000_R19","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1001\/jama.1985.03360140090031","article-title":"Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality","volume":"254","author":"Grimm Jr","year":"1985","journal-title":"JAMA"},{"key":"2020071613534009000_R20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0002-8703(92)90942-O","article-title":"The white blood cell count and risk for coronary heart disease","volume":"124","author":"Ensrud","year":"1992","journal-title":"Am Heart J"},{"key":"2020071613534009000_R21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1992.03480090101035","article-title":"White blood cell count and cardiovascular disease. Insights from the Framingham Study","volume":"267","author":"Kannel","year":"1992","journal-title":"JAMA"},{"key":"2020071613534009000_R22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.CIR.99.2.237","article-title":"C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992","volume":"99","author":"Koenig","year":"1999","journal-title":"Circulation"},{"key":"2020071613534009000_R23","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1161\/01.ATV.19.10.2355","article-title":"Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries","volume":"19","author":"Erren","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020071613534009000_R24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071613534009000_R25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0021-9150(99)00371-8","article-title":"Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery","volume":"150","author":"Pasterkamp","year":"2000","journal-title":"Atherosclerosis"},{"key":"2020071613534009000_R26","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1073\/pnas.91.11.4854","article-title":"Tumor necrosis factor \u03b1 inhibits signaling from the insulin receptor","volume":"91","author":"Hotamisligil","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071613534009000_R27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.271.5249.665","article-title":"IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-\u03b1- and obesity-induced insulin resistance","volume":"271","author":"Hotamisligil","year":"1996","journal-title":"Science"},{"key":"2020071613534009000_R28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/meta.2002.31339","article-title":"Tumor necrosis factor-\u03b1 inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells","volume":"51","author":"Aljada","year":"2002","journal-title":"Metabolism"},{"key":"2020071613534009000_R29","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1210\/jcem.85.8.6854","article-title":"Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes","volume":"85","author":"Mohanty","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613534009000_R30","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1172\/JCI26045","article-title":"Insulin infusion in acute illness","volume":"115","author":"Dandona","year":"2005","journal-title":"J Clin Invest"},{"key":"2020071613534009000_R31","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1210\/jc.2005-0223","article-title":"Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment","volume":"90","author":"Dhindsa","year":"2005","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/91\/9\/3553\/9064594\/jcem3553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/91\/9\/3553\/9064594\/jcem3553.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:53:56Z","timestamp":1594947236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/91\/9\/3553\/2656742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2005-2609","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}